ACADIA Pharmaceuticals Inc. (ACAD) NASDAQ
21.99
-0.25(-1.12%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
21.99
-0.25(-1.12%)
Currency In USD
Address
12830 El Camino Real
San Diego, CA 92130
United States of America (the)
Phone
858 558 2871
Website
Sector
Healthcare
Industry
Biotechnology
Employees
653
First IPO Date
May 27, 2004
| Name | Title | Pay | Year Born |
| Catherine E. Owen Adams | Chief Executive Officer & Director | 955,940 | 1970 |
| Elizabeth Thompson | Executive Vice President and Head of Research & Development | 507,080 | 1975 |
| Jennifer J. Rhodes | Executive VP, Chief Legal Officer & Secretary | 732,924 | 1970 |
| Thomas Andrew Garner | Executive VP & Chief Commercial Officer | 737,001 | 1976 |
| Mark C. Schneyer | Executive VP & CFO | 791,900 | 1974 |
| Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| James K. Kihara | Senior Vice President of Finance | 0 | 1981 |
| Rob Ackles | Senior VP & Chief People Officer | 0 | N/A |
| Scott Cenci | Senior VP, Chief Information & Data Officer | 0 | N/A |
| Allyson McMillan Youngblood | Senior Vice President of Rare Disease Franchise | 0 | N/A |
| Konstantina Katcheves | Senior Vice President, Chief Business & Strategy Officer | 0 | N/A |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.